{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:28:22Z","timestamp":1792549702080,"version":"4.5.0"},"reference-count":261,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,9,5]]},"published-print":{"date-parts":[[2025,6]]},"DOI":"10.2967\/jnumed.124.268756","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:25:15Z","timestamp":1736324715000},"page":"S5-S31","source":"Crossref","is-referenced-by-count":83,"title":["Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup"],"prefix":"10.2967","volume":"66","author":[{"given":"Gil D.","family":"Rabinovici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammie L.S.","family":"Benzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Donohoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Herscovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Lingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Minoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025060610150794000_66.Supplement_2.S5.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0910-3"},{"key":"2025060610150794000_66.Supplement_2.S5.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.10.007"},{"key":"2025060610150794000_66.Supplement_2.S5.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302548"},{"key":"2025060610150794000_66.Supplement_2.S5.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.109009"},{"key":"2025060610150794000_66.Supplement_2.S5.5","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7"},{"key":"2025060610150794000_66.Supplement_2.S5.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22068"},{"key":"2025060610150794000_66.Supplement_2.S5.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3749-6"},{"key":"2025060610150794000_66.Supplement_2.S5.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171595"},{"key":"2025060610150794000_66.Supplement_2.S5.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.9"},{"key":"2025060610150794000_66.Supplement_2.S5.10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"54 9","author":"Johnson","year":"2013","journal-title":"J Nucl Med."},{"key":"2025060610150794000_66.Supplement_2.S5.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.127068"},{"key":"2025060610150794000_66.Supplement_2.S5.13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.14","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.15","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"2025060610150794000_66.Supplement_2.S5.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2025060610150794000_66.Supplement_2.S5.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2025060610150794000_66.Supplement_2.S5.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2025060610150794000_66.Supplement_2.S5.19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"2025060610150794000_66.Supplement_2.S5.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.09.012"},{"key":"2025060610150794000_66.Supplement_2.S5.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"2025060610150794000_66.Supplement_2.S5.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2025060610150794000_66.Supplement_2.S5.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"2025060610150794000_66.Supplement_2.S5.24","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31824b211b"},{"key":"2025060610150794000_66.Supplement_2.S5.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30440-3"},{"key":"2025060610150794000_66.Supplement_2.S5.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1717-7"},{"key":"2025060610150794000_66.Supplement_2.S5.27","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2025060610150794000_66.Supplement_2.S5.28","unstructured":"Neuraceq. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204677Orig1s000SumR.pdf. Approved March 19, 2014."},{"key":"2025060610150794000_66.Supplement_2.S5.29","unstructured":"Flutemetamol. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203137s008lbl.pdf. Approved October 27, 2013."},{"key":"2025060610150794000_66.Supplement_2.S5.30","unstructured":"Amyvid. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202008s000lbl.pdf. Approved April 6, 2012."},{"key":"2025060610150794000_66.Supplement_2.S5.31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/ph14020110","article-title":"Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease","volume":"14","author":"Jie","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2025060610150794000_66.Supplement_2.S5.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.174615"},{"key":"2025060610150794000_66.Supplement_2.S5.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"2025060610150794000_66.Supplement_2.S5.34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.004"},{"key":"2025060610150794000_66.Supplement_2.S5.36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv050"},{"key":"2025060610150794000_66.Supplement_2.S5.37","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018180160"},{"key":"2025060610150794000_66.Supplement_2.S5.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05784-y"},{"key":"2025060610150794000_66.Supplement_2.S5.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.09.001"},{"key":"2025060610150794000_66.Supplement_2.S5.40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00836-1"},{"key":"2025060610150794000_66.Supplement_2.S5.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264031"},{"key":"2025060610150794000_66.Supplement_2.S5.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265766"},{"key":"2025060610150794000_66.Supplement_2.S5.43","unstructured":"Tauvid. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212123s000lbl.pdf. Revised May 2020."},{"key":"2025060610150794000_66.Supplement_2.S5.44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263196"},{"key":"2025060610150794000_66.Supplement_2.S5.45","doi-asserted-by":"crossref","first-page":"e12454","DOI":"10.1002\/dad2.12454","article-title":"CenTauR: Toward a universal scale and masks for standardizing tau imaging studies","volume":"15","author":"Villemagne","year":"2023","journal-title":"Alzheimers Dement (Amst)."},{"key":"2025060610150794000_66.Supplement_2.S5.46","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1002\/alz.13908","article-title":"Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: The CenTauR scale and the joint propagation model","volume":"20","author":"Leuzy","year":"2024","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-023-01160-6","article-title":"Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression","volume":"15","author":"Kotari","year":"2023","journal-title":"Alzheimers Res Ther."},{"key":"2025060610150794000_66.Supplement_2.S5.48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.49","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2025060610150794000_66.Supplement_2.S5.50","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0127-z"},{"key":"2025060610150794000_66.Supplement_2.S5.51","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"2025060610150794000_66.Supplement_2.S5.52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.4.479"},{"key":"2025060610150794000_66.Supplement_2.S5.53","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww027"},{"key":"2025060610150794000_66.Supplement_2.S5.54","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004643"},{"key":"2025060610150794000_66.Supplement_2.S5.55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/acn3.51238","article-title":"Association of PET-based stages of amyloid deposition with neuropathological markers of A\u03b2 pathology","volume":"8","author":"Teipel","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.56","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000140289.18472.15"},{"key":"2025060610150794000_66.Supplement_2.S5.57","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws076"},{"key":"2025060610150794000_66.Supplement_2.S5.58","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.10.1233"},{"key":"2025060610150794000_66.Supplement_2.S5.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70156-9"},{"key":"2025060610150794000_66.Supplement_2.S5.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02036-6"},{"key":"2025060610150794000_66.Supplement_2.S5.61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3233\/JAD-190264","article-title":"Tau subtypes of Alzheimer\u2019s disease determined in vivo using flortaucipir PET imaging","volume":"71","author":"Charil","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.62","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011270"},{"key":"2025060610150794000_66.Supplement_2.S5.63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-016-0399-z","article-title":"Post-mortem histopathology underlying \u03b2-amyloid PET imaging following flutemetamol F 18 injection","volume":"4","author":"Ikonomovic","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"2025060610150794000_66.Supplement_2.S5.64","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","article-title":"Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall","year":"2021","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00401-020-02175-1","article-title":"Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-\u03b2 plaques in Alzheimer\u2019s disease","volume":"140","author":"Ikonomovic","year":"2020","journal-title":"Acta Neuropathol (Berl)."},{"key":"2025060610150794000_66.Supplement_2.S5.66","first-page":"1","article-title":"Neuropathology of the Alzheimer\u2019s continuum: an update","volume":"1","author":"Jellinger","year":"2020","journal-title":"Free Neuropathol."},{"key":"2025060610150794000_66.Supplement_2.S5.67","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30314-8"},{"key":"2025060610150794000_66.Supplement_2.S5.68","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25968"},{"key":"2025060610150794000_66.Supplement_2.S5.69","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1133"},{"key":"2025060610150794000_66.Supplement_2.S5.70","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000734"},{"key":"2025060610150794000_66.Supplement_2.S5.71","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.065870"},{"key":"2025060610150794000_66.Supplement_2.S5.72","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00259-018-4031-2","article-title":"Clinical utility of FDG PET in Parkinson\u2019s disease and atypical parkinsonism associated with dementia","volume":"45","author":"Walker","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060610150794000_66.Supplement_2.S5.73","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003512"},{"key":"2025060610150794000_66.Supplement_2.S5.74","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324606"},{"key":"2025060610150794000_66.Supplement_2.S5.75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.76","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229443"},{"key":"2025060610150794000_66.Supplement_2.S5.77","doi-asserted-by":"crossref","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","article-title":"Imaging of synaptic density in neurodegenerative disorders","volume":"63","author":"Carson","year":"2012","journal-title":"J Nucl Med."},{"key":"2025060610150794000_66.Supplement_2.S5.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3"},{"key":"2025060610150794000_66.Supplement_2.S5.79","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00779"},{"key":"2025060610150794000_66.Supplement_2.S5.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.004"},{"key":"2025060610150794000_66.Supplement_2.S5.81","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200040"},{"key":"2025060610150794000_66.Supplement_2.S5.82","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114398"},{"key":"2025060610150794000_66.Supplement_2.S5.83","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00578-0"},{"key":"2025060610150794000_66.Supplement_2.S5.84","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"2025060610150794000_66.Supplement_2.S5.86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0"},{"key":"2025060610150794000_66.Supplement_2.S5.88","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012727"},{"key":"2025060610150794000_66.Supplement_2.S5.89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02443-z"},{"key":"2025060610150794000_66.Supplement_2.S5.90","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001991"},{"key":"2025060610150794000_66.Supplement_2.S5.91","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging."},{"key":"2025060610150794000_66.Supplement_2.S5.92","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2025060610150794000_66.Supplement_2.S5.93","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2025060610150794000_66.Supplement_2.S5.94","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12801"},{"key":"2025060610150794000_66.Supplement_2.S5.95","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/alz.12706","article-title":"Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models","volume":"19","author":"Cullen","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"2025060610150794000_66.Supplement_2.S5.97","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02195-x"},{"key":"2025060610150794000_66.Supplement_2.S5.98","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"key":"2025060610150794000_66.Supplement_2.S5.99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0762-2"},{"key":"2025060610150794000_66.Supplement_2.S5.100","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02275-6"},{"key":"2025060610150794000_66.Supplement_2.S5.101","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2025060610150794000_66.Supplement_2.S5.102","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAC333"},{"key":"2025060610150794000_66.Supplement_2.S5.103","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00214-3"},{"key":"2025060610150794000_66.Supplement_2.S5.104","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nat Aging."},{"key":"2025060610150794000_66.Supplement_2.S5.105","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01384-9"},{"key":"2025060610150794000_66.Supplement_2.S5.106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0"},{"key":"2025060610150794000_66.Supplement_2.S5.107","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with alzheimer disease for antiamyloid immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.109","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.12395"},{"key":"2025060610150794000_66.Supplement_2.S5.110","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.111","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"key":"2025060610150794000_66.Supplement_2.S5.112","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01822-2"},{"key":"2025060610150794000_66.Supplement_2.S5.113","first-page":"S36","article-title":"Plasma MTBR-tau243 is a specific biomarker tau tangle pathology in Alzheimer\u2019s disease","volume":"10","author":"Horie","year":"2023","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.114","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387"},{"key":"2025060610150794000_66.Supplement_2.S5.115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.116","unstructured":"Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011."},{"key":"2025060610150794000_66.Supplement_2.S5.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.008"},{"key":"2025060610150794000_66.Supplement_2.S5.118","unstructured":"Fitch K Bernstein SJ Aguilar MD . The RAND\/UCLA Appropriateness Method User\u2019s Manual. RAND Corporation; 2001."},{"key":"2025060610150794000_66.Supplement_2.S5.119","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-6-9"},{"key":"2025060610150794000_66.Supplement_2.S5.120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.dadm.2018.05.003","article-title":"Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure","volume":"10","author":"Lingler","year":"2018","journal-title":"Alzheimers Dement (Amst)."},{"key":"2025060610150794000_66.Supplement_2.S5.121","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12152-017-9313-z","article-title":"Amnestic MCI patients\u2019 perspectives toward disclosure of amyloid PET results in a research context","volume":"10","author":"Vanderschaeghe","year":"2017","journal-title":"Neuroethics."},{"key":"2025060610150794000_66.Supplement_2.S5.122","doi-asserted-by":"crossref","first-page":"958","DOI":"10.14283\/jpad.2024.50","article-title":"Value of knowing: health-related behavior changes following amyloid PET results disclosure in mild cognitive impairment","volume":"11","author":"Wang","year":"2024","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.123","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.124","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4669"},{"key":"2025060610150794000_66.Supplement_2.S5.125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/bs.pmbts.2019.05.002","article-title":"Disclosure of amyloid PET scan results: a systematic review","volume":"165","author":"Kim","year":"2019","journal-title":"Prog Mol Biol Transl Sci."},{"key":"2025060610150794000_66.Supplement_2.S5.126","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13410"},{"key":"2025060610150794000_66.Supplement_2.S5.127","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2017.12962","article-title":"Elevated brain amyloid in cognitively normal individuals: reply","volume":"318","author":"Donohue","year":"2017","journal-title":"JAMA."},{"key":"2025060610150794000_66.Supplement_2.S5.128","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","article-title":"Early and late change on the preclinical Alzheimer\u2019s cognitive composite in clinically normal older individuals with elevated amyloid beta","volume":"13","author":"Mormino","year":"2017","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.129","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70194-7"},{"key":"2025060610150794000_66.Supplement_2.S5.130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.131","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24546"},{"key":"2025060610150794000_66.Supplement_2.S5.132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc0655"},{"key":"2025060610150794000_66.Supplement_2.S5.133","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02049-x"},{"key":"2025060610150794000_66.Supplement_2.S5.134","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","article-title":"Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment","volume":"79","author":"Strikwerda-Brown","year":"2022","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaneurol.2023.2560","article-title":"Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-\u03b2 positivity","volume":"80","author":"Costoya-S\u00e1nchez","year":"2023","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.136","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.137","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"2025060610150794000_66.Supplement_2.S5.138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","article-title":"Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community","volume":"73","author":"Petersen","year":"2016","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.01.001"},{"key":"2025060610150794000_66.Supplement_2.S5.140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13195-020-00734-y","article-title":"Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study","volume":"12","author":"R\u00f6hr","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"2025060610150794000_66.Supplement_2.S5.141","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000856"},{"key":"2025060610150794000_66.Supplement_2.S5.142","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000005863"},{"key":"2025060610150794000_66.Supplement_2.S5.143","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30029-2"},{"key":"2025060610150794000_66.Supplement_2.S5.144","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032816-045136"},{"key":"2025060610150794000_66.Supplement_2.S5.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2012.08.011"},{"key":"2025060610150794000_66.Supplement_2.S5.146","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jamaneurol.2017.2216","article-title":"Region-specific association of subjective cognitive decline with tauopathy independent of global \u03b2-amyloid burden","volume":"74","author":"Buckley","year":"2017","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.147","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.3233\/JAD-150113","article-title":"Amyloid-\u03b2 imaging in older adults presenting to a memory clinic with subjective cognitive decline: a pilot study","volume":"48","author":"Snitz","year":"2015","journal-title":"J Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.148","first-page":"e12127","article-title":"Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE \u03b54","volume":"12","author":"S\u00e1nchez-Benavides","year":"2020","journal-title":"Alzheimers Dement (Amst)."},{"key":"2025060610150794000_66.Supplement_2.S5.149","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.trci.2018.08.005","article-title":"Amyloid-associated increases in longitudinal report of subjective cognitive complaints","volume":"4","author":"Amariglio","year":"2018","journal-title":"Alzheimers Dement (N Y)."},{"key":"2025060610150794000_66.Supplement_2.S5.150","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0000000000004627","article-title":"Subjective cognitive decline and \u03b2-amyloid burden predict cognitive change in healthy elderly","volume":"89","author":"Vogel","year":"2017","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.151","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neurobiolaging.2019.02.020","article-title":"Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol Aging."},{"key":"2025060610150794000_66.Supplement_2.S5.152","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70159-9"},{"key":"2025060610150794000_66.Supplement_2.S5.153","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2021.2161","article-title":"Global prevalence of young-onset dementia: a systematic review and meta-analysis","volume":"78","author":"Hendriks","year":"2021","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.154","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1908-x"},{"key":"2025060610150794000_66.Supplement_2.S5.155","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.3.326"},{"key":"2025060610150794000_66.Supplement_2.S5.156","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821a44dd"},{"key":"2025060610150794000_66.Supplement_2.S5.157","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaneurol.2019.3606","article-title":"Selective vulnerability of the nucleus basalis of meynert among neuropathologic subtypes of Alzheimer disease","volume":"77","author":"Hanna Al-Shaikh","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.158","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab099"},{"key":"2025060610150794000_66.Supplement_2.S5.159","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx171"},{"key":"2025060610150794000_66.Supplement_2.S5.160","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz099"},{"key":"2025060610150794000_66.Supplement_2.S5.161","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/alz.13453","article-title":"Amyloid and tau-PET in early-onset AD: baseline data from the longitudinal early-onset Alzheimer\u2019s disease study (LEADS)","volume":"19","author":"Cho","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.162","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","article-title":"Tau-positron emission tomography correlates with neuropathology findings","volume":"16","author":"Lowe","year":"2020","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.163","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa276"},{"key":"2025060610150794000_66.Supplement_2.S5.164","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00169-5"},{"key":"2025060610150794000_66.Supplement_2.S5.165","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.22927"},{"key":"2025060610150794000_66.Supplement_2.S5.166","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2000"},{"key":"2025060610150794000_66.Supplement_2.S5.167","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/14737175.2015.1023296","article-title":"The role of positron emission tomography imaging in understanding Alzheimer\u2019s disease","volume":"15","author":"Barthel","year":"2015","journal-title":"Expert Rev Neurother."},{"key":"2025060610150794000_66.Supplement_2.S5.168","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668"},{"key":"2025060610150794000_66.Supplement_2.S5.169","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000320506.79811.da"},{"key":"2025060610150794000_66.Supplement_2.S5.170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.01.014"},{"key":"2025060610150794000_66.Supplement_2.S5.171","doi-asserted-by":"crossref","first-page":"fcaa068","DOI":"10.1093\/braincomms\/fcaa068","article-title":"Progressive dysexecutive syndrome due to Alzheimer\u2019s disease: a description of 55 cases and comparison to other phenotypes","volume":"2","author":"Townley","year":"2020","journal-title":"Brain Commun."},{"key":"2025060610150794000_66.Supplement_2.S5.172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2025060610150794000_66.Supplement_2.S5.173","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00066-1"},{"key":"2025060610150794000_66.Supplement_2.S5.174","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaneurol.2021.4417","article-title":"Research criteria for the behavioral variant of Alzheimer disease: a systematic review and meta-analysis","volume":"79","author":"Ossenkoppele","year":"2022","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.175","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24885"},{"key":"2025060610150794000_66.Supplement_2.S5.176","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25333"},{"key":"2025060610150794000_66.Supplement_2.S5.177","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00414-3"},{"key":"2025060610150794000_66.Supplement_2.S5.178","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22424"},{"key":"2025060610150794000_66.Supplement_2.S5.179","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx254"},{"key":"2025060610150794000_66.Supplement_2.S5.180","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.0000000000001376","article-title":"Differences in Alzheimer disease clinical trial outcomes based on age of the participants","volume":"84","author":"Schneider","year":"2015","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.181","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21706"},{"key":"2025060610150794000_66.Supplement_2.S5.182","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww159"},{"key":"2025060610150794000_66.Supplement_2.S5.183","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.24473.Regional"},{"key":"2025060610150794000_66.Supplement_2.S5.184","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2016.5755","article-title":"Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease","volume":"74","author":"Xia","year":"2017","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/brain\/awaa383","article-title":"18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome","volume":"144","author":"Goodheart","year":"2021","journal-title":"Brain."},{"key":"2025060610150794000_66.Supplement_2.S5.186","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.187","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamaneurol.2020.5505","article-title":"Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials","volume":"78","author":"Lu","year":"2021","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.188","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"2025060610150794000_66.Supplement_2.S5.189","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/jamaneurol.2019.4509","article-title":"Tau positron emission tomographic findings in a former US football player with pathologically confirmed chronic traumatic encephalopathy","volume":"77","author":"Mantyh","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.190","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182840bbe"},{"key":"2025060610150794000_66.Supplement_2.S5.191","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22248"},{"key":"2025060610150794000_66.Supplement_2.S5.192","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12917"},{"key":"2025060610150794000_66.Supplement_2.S5.193","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"2025060610150794000_66.Supplement_2.S5.194","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00109-6"},{"key":"2025060610150794000_66.Supplement_2.S5.195","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009323"},{"key":"2025060610150794000_66.Supplement_2.S5.196","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1212\/WNL.0000000000011454","article-title":"\u03b2-Amyloid PET and 123I-FP-CIT SPECT in mild cognitive impairment at risk for Lewy body dementia","volume":"96","author":"Chen","year":"2021","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.197","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.03.001"},{"key":"2025060610150794000_66.Supplement_2.S5.198","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-008-0347-5"},{"key":"2025060610150794000_66.Supplement_2.S5.199","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12182"},{"key":"2025060610150794000_66.Supplement_2.S5.200","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23041-x"},{"key":"2025060610150794000_66.Supplement_2.S5.201","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau positron emission tomographic imaging in the Lewy body diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.202","doi-asserted-by":"crossref","first-page":"e1850","DOI":"10.1212\/WNL.0000000000207794","article-title":"Performance of a [18F]flortaucipir PET visual read method across the Alzheimer disease continuum and in dementia with Lewy bodies","volume":"101","author":"Coomans","year":"2023","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.203","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24825"},{"key":"2025060610150794000_66.Supplement_2.S5.204","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mds.27252","article-title":"Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases","volume":"33","author":"Lee","year":"2018","journal-title":"Mov Disord."},{"key":"2025060610150794000_66.Supplement_2.S5.205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neurobiolaging.2020.11.006","article-title":"Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography","volume":"101","author":"Mak","year":"2021","journal-title":"Neurobiol Aging."},{"key":"2025060610150794000_66.Supplement_2.S5.206","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neurobiolaging.2020.08.003","article-title":"Multimodal in vivo and postmortem assessments of tau in Lewy body disorders","volume":"96","author":"Coughlin","year":"2020","journal-title":"Neurobiol Aging."},{"key":"2025060610150794000_66.Supplement_2.S5.207","doi-asserted-by":"crossref","first-page":"e042856","DOI":"10.1002\/alz.042856","article-title":"Neuroimaging biomarkers in prodromal DLB","volume":"16","author":"Kantarci","year":"2020","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.208","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x"},{"key":"2025060610150794000_66.Supplement_2.S5.209","doi-asserted-by":"crossref","first-page":"508\u2013516","DOI":"10.1001\/jamaneurol.2019.4749","article-title":"Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography","volume":"77","author":"Meyer","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.210","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007901"},{"key":"2025060610150794000_66.Supplement_2.S5.211","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0781-z"},{"key":"2025060610150794000_66.Supplement_2.S5.212","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy059"},{"key":"2025060610150794000_66.Supplement_2.S5.213","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-021-01309-6"},{"key":"2025060610150794000_66.Supplement_2.S5.214","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-190818","article-title":"improved risk stratification for progression from mild cognitive impairment to Alzheimer\u2019s disease with a multi-analytical evaluation of amyloid-\u03b2 positron emission tomography","volume":"74","author":"Beyer","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-017-0260-z","article-title":"The Alzheimer\u2019s disease neuroimaging I: comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer\u2019s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database","volume":"9","author":"Ben Bouall\u00e8gue","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"2025060610150794000_66.Supplement_2.S5.216","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.230797"},{"key":"2025060610150794000_66.Supplement_2.S5.217","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JAD-190070","article-title":"Alzheimer\u2019s disease neuroimaging I: quantitative brain amyloid measures predict time-to-progression from amnestic mild cognitive impairment to Alzheimer\u2019s disease","volume":"70","author":"Jun","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.218","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","article-title":"Initiative ftAsDN: comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes","volume":"72","author":"Schreiber","year":"2015","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.219","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00259-019-04409-1","article-title":"Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-\u03b2 neocortical deposition","volume":"46","author":"Ciarmiello","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060610150794000_66.Supplement_2.S5.220","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.9"},{"key":"2025060610150794000_66.Supplement_2.S5.221","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12129"},{"key":"2025060610150794000_66.Supplement_2.S5.222","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012022"},{"key":"2025060610150794000_66.Supplement_2.S5.223","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.224","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq277"},{"key":"2025060610150794000_66.Supplement_2.S5.225","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"2025060610150794000_66.Supplement_2.S5.226","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"2025060610150794000_66.Supplement_2.S5.227","unstructured":"FDA. Package insert for aducanumab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s000lbl.pdf. Approved June 7, 2021."},{"key":"2025060610150794000_66.Supplement_2.S5.228","unstructured":"FDA. Package insert for lecanemab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf. Approved July 6, 2023."},{"key":"2025060610150794000_66.Supplement_2.S5.229","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.231","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.232","unstructured":"Donanemab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf. Approved July 2, 2024."},{"key":"2025060610150794000_66.Supplement_2.S5.233","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.semnuclmed.2016.09.005","article-title":"Clinical amyloid imaging","volume":"47","author":"Mallik","year":"2017","journal-title":"Semin Nucl Med."},{"key":"2025060610150794000_66.Supplement_2.S5.234","first-page":"S10","article-title":"Biomarker assessments from clarity AD: downstream implications of targeting protofibrils and tau as a predictive biomarker","volume":"12","author":"Johnson","year":"2023","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.235","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"2025060610150794000_66.Supplement_2.S5.236","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2025060610150794000_66.Supplement_2.S5.237","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14283\/jpad.2020.68","article-title":"Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab","volume":"8","author":"Klein","year":"2021","journal-title":"J Prev Alzheimers Dis."},{"key":"2025060610150794000_66.Supplement_2.S5.238","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"2025060610150794000_66.Supplement_2.S5.239","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"2025060610150794000_66.Supplement_2.S5.240","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer\u2019s disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain."},{"key":"2025060610150794000_66.Supplement_2.S5.241","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01405-0"},{"key":"2025060610150794000_66.Supplement_2.S5.242","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology."},{"key":"2025060610150794000_66.Supplement_2.S5.243","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.244","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000596"},{"key":"2025060610150794000_66.Supplement_2.S5.245","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn107"},{"key":"2025060610150794000_66.Supplement_2.S5.246","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02342-y"},{"key":"2025060610150794000_66.Supplement_2.S5.247","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"2025060610150794000_66.Supplement_2.S5.248","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","article-title":"Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison","volume":"48","author":"Altomare","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060610150794000_66.Supplement_2.S5.249","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaneurol.2023.1323","article-title":"Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms","volume":"80","author":"Smith","year":"2023","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.250","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the imaging dementia\u2013evidence for amyloid scanning (IDEAS) cohort study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.251","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011599"},{"key":"2025060610150794000_66.Supplement_2.S5.252","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26819"},{"key":"2025060610150794000_66.Supplement_2.S5.253","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/alz.12797","article-title":"Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer\u2019s disease neuroimaging initiative 4","volume":"19","author":"Weiner","year":"2023","journal-title":"Alzheimers Dement."},{"key":"2025060610150794000_66.Supplement_2.S5.254","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02326-3"},{"key":"2025060610150794000_66.Supplement_2.S5.255","unstructured":"Alz-net. Available from: https:\/\/www.alz-net.org\/."},{"key":"2025060610150794000_66.Supplement_2.S5.256","doi-asserted-by":"crossref","first-page":"118775","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage."},{"key":"2025060610150794000_66.Supplement_2.S5.257","doi-asserted-by":"crossref","first-page":"e12372","DOI":"10.1002\/trc2.12372","article-title":"Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET","volume":"9","author":"Shuping","year":"2023","journal-title":"Alzheimers Dement (N Y)."},{"key":"2025060610150794000_66.Supplement_2.S5.258","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264371"},{"key":"2025060610150794000_66.Supplement_2.S5.259","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05152-8"},{"key":"2025060610150794000_66.Supplement_2.S5.260","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/jamaneurol.2023.3490","article-title":"Amyloid positron emission tomography and subsequent health care use among medicare beneficiaries with mild cognitive impairment or dementia","volume":"80","author":"Rabinovici","year":"2023","journal-title":"JAMA Neurol."},{"key":"2025060610150794000_66.Supplement_2.S5.261","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/alz.12846","article-title":"A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting","volume":"19","author":"van Maurik","year":"2023","journal-title":"Alzheimers Dement."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:16:52Z","timestamp":1749215812000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":261,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2025,6,6]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.2967\/jnumed.124.268756"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268756","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}